Glucotrack revises terms of $900K note exchange and files superseding agreement
GCTK is trading near its 52-week low of $0.25 (14% above the low) on light trading volume (0.2× avg).
Summary
Glucotrack amended its recent 8-K to update the terms of a $900,000 note exchange, filing the superseding agreement. The note can be converted into common stock at a price based on recent market prices, potentially adding to dilution for a company already facing going concern and delisting risks.
Key Events · Financing and Capital Events · GCTK
-
Amendment Updates $900K Note Exchange Terms
The 8-K/A updates the description of the Exchange Agreement and files the superseding agreement dated July 24, 2026, replacing the original July 22 agreement.
-
Conversion Price Tied to Market
The $900,000 Partitioned Note converts into common stock at the lower of the Nasdaq closing price immediately before execution or the five-day average, which at current prices could mean substantial share issuance.
-
Dilution Risk Amid Financial Distress
The company already faces a going concern warning, Nasdaq delisting notices, and a recent reverse merger. This note conversion adds to the dilution overhang as the company seeks to avoid collapse.
-
Shares to Be Delivered by August 31, 2026
The Exchange Shares must be delivered to the investor on or before August 31, 2026, with the note cancelled upon delivery.
Analysis · GCTK · Industrial Applications And Services
Glucotrack filed an amendment to its July 27 8-K, updating the terms of a $900,000 promissory note exchange and filing the superseding agreement. The new Exchange Agreement, dated July 24, replaces the original July 22 agreement. The note was partitioned from a larger $3.6M note, and the holder can convert it into common stock at a price equal to the lower of the Nasdaq closing price immediately before execution or the five-day average. With the stock at $0.2845, this could result in significant dilution. The company is already under severe financial stress, with a going concern warning, delisting notices, and a recent reverse merger that handed 90% control to Lokahi Therapeutics. This amendment clarifies the conversion mechanics, which could add to the dilution overhang as the company fights for survival.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCTK was trading at $0.28 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.25 to $14.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.